Business
DCC Healthcare announces acquisition of Amerilab
DCC Healthcare announces acquisition of Amerilab.
About this update from Dcc Plc
[{"type":"text","content":"\n \n \n RNS Number : 5165H\n DCC PLC\n 25 March 2020\n \n \n \n \n \n \n \n \n \n \n 25 March 2020\n \n \n \n \n \n DCC Healthcare announces the acquisition of Amerilab Technologies\n \n \n \n \n \n DCC plc, the leading international sales, marketing and \n support services group, \n announces that DCC Health & Beauty Solutions has acquired Amerilab Technologies, Inc ('Amerilab'), a specialist provider of contract manufacturing and related services in effervescent nutritional products, based near Minneapolis, in Plymouth, Minnesota. \n The acquisition of Amerilab \n is DCC Health & Beauty Solutions' third acquisition in the US market, following the acquisition of Ion Labs in November 2019 and Elite One Source in February 2018. It \n is a further significant step in the execution of the strategy to build a business of scale in the world's largest health supplements and nutritional products market\n . \n \n \n \n \n \n Amerilab specialises in the manufacture of effervescent nutritional products in powder and tablet formats, which are packed in stickpacks, sachets and tubes. Its service offering includes product development, formulation, manufacturing, packaging and regulatory services. Amerilab operates from a large, well-invested facility, which \n complies with \n FDA cGMP (current Good Manufacturing Practices) and is certified by leading international regulatory bodies, NSF and the TGA (Australia's Therapeutic Goods Association). In recent years Amerilab has invested in high-speed, automated equipment, enhancing its operational efficiency and increasing manufacturing capacity. Amerilab's customer base consists of high-quality consumer healthcare companies, specialty brand owners and direct sales organisations. Effervescents are a higher growth product segment within the US nutritional market, with attractive demographic characteristics and environmental credentials. \n Amerilab's complementary effervescent capability will create opportunities for cross-selling and other synergies with DCC Health & Beauty Solutions.\n \n \n \n \n \n \n The business, which employs 125 people and has revenues of approximately $68 million, will continue to be led by its experienced management team. DCC is acquiring Amerilab based on an enterprise value of approximately $85 million (£72 mi...